Physician profile
Bradley Phillip Katz
NPI 1891841581
$11,855.17
in general payments reported to CMS, 2019-2025
43 companies · $1,244 in 2025
The $1,244 reported for 2025 was more than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,466 · 2020: $2,099 · 2021: $2,294 · 2022: $2,039 · 2023: $1,061 · 2024: $1,651 · 2025: $1,244.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,957.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,956.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $7,690.49 | 2019-2025 | Proclaim, Eterna |
| Boston Scientific Corporation | $903.22 | 2019-2025 | Infinion 16, Artisan, Infinion 16 |
| Collegium Pharmaceutical, INC. | $534.37 | 2019-2025 | Belbuca, Xtampza |
| Scilex Pharmaceuticals INC. | $306.86 | 2019-2024 | Ztlido |
| Nevro Corp. | $257.42 | 2019-2023 | Senza |
| Arbor Pharmaceuticals, INC. | $214.30 | 2019-2022 | |
| Amgen INC. | $208.63 | 2019-2022 | |
| Abbvie INC. | $158.46 | 2022-2025 | |
| Forte Bio-Pharma LLC | $147.71 | 2022-2024 | Prolate, Nalocet |
| Pfizer INC. | $122.02 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $118.19 | 2019-2021 | |
| Curonix LLC | $97.95 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Azurity Pharmaceuticals, INC. | $72.45 | 2023-2024 | Horizant, Horizant |
| Biodelivery Sciences International, INC. | $72.07 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $59.62 | 2021-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bradley Katz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.